A detailed history of Tevis Investment Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Tevis Investment Management holds 1,042 shares of VRTX stock, worth $515,383. This represents 0.36% of its overall portfolio holdings.

Number of Shares
1,042
Previous 851 22.44%
Holding current value
$515,383
Previous $398,000 21.61%
% of portfolio
0.36%
Previous 0.32%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$460.0 - $505.78 $87,860 - $96,603
191 Added 22.44%
1,042 $484,000
Q2 2024

Jul 23, 2024

SELL
$392.81 - $485.53 $9,427 - $11,652
-24 Reduced 2.74%
851 $398,000
Q1 2024

Apr 16, 2024

BUY
$407.69 - $446.08 $32,207 - $35,240
79 Added 9.92%
875 $365,000
Q4 2023

Jan 19, 2024

SELL
$343.0 - $410.68 $18,865 - $22,587
-55 Reduced 6.46%
796 $323,000
Q3 2023

Oct 16, 2023

BUY
$338.18 - $362.46 $287,791 - $308,453
851 New
851 $295,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $127B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Tevis Investment Management Portfolio

Follow Tevis Investment Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tevis Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Tevis Investment Management with notifications on news.